Actively Recruiting

Phase Not Applicable
Age: 65Years +
All Genders
ID06674252

A Randomized Controlled Multicenter Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery

Led by Peking University Cancer Hospital & Institute · Updated on 2026-01-27

174

Participants Needed

2

Research Sites

13 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to evaluate the effects of a traditional Chinese medicine formula called Jiawei Bufei Tang on elderly patients who have undergone lung cancer surgery and experience symptoms like cough, shortness of breath, and fatigue. This randomized, double-blind, placebo-controlled phase II trial focuses on improving postoperative symptoms and potentially enhancing survival benefits in this patient group. The study uses the MDASI-TCM symptom scoring system to assess symptom changes and compare outcomes between the treatment and control groups. Participants are randomly assigned to one of two groups: the treatment group receives Jiawei Bufei Tang granules, and the control group receives a placebo that looks and tastes similar. Both groups take one packet orally with water twice daily for 28 consecutive days, starting from the seventh day after surgery. The granules are produced in the same batch and packaged identically to maintain blinding. If participants experience discomfort, unblinding or withdrawal may occur based on the researcher's judgement. During the study, patients are evaluated using the MDASI-TCM scale before starting treatment and after 28 days to measure symptoms such as cough, fatigue, and shortness of breath. Additional assessments include the QLQ-C30 quality of life scale, comprehensive geriatric assessment (CGA), and disease-free survival (DFS) within the 28-day period. Participants are monitored closely throughout the treatment for safety and symptom changes. The total participation duration is approximately one month from enrollment to final evaluation.

CONDITIONS

Brief Title

A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery

Who Can Participate

Age: 65Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with postoperative lung cancer who have a clear histological or cytological diagnosis.
  • Age 65 years or older, both male and female are eligible.
  • Symptoms of cough, fatigue, or shortness of breath scoring 4 points or higher on the MDASI-TCM scale, or a combined score of 6 points or higher.
  • Heart function is basically normal.
  • Liver enzymes (ALT/AST) are within two times the normal value.
  • Serum creatinine (SCr) is within the normal range.
  • Traditional Chinese medicine diagnosis of deficiency of both lungs and kidneys.
Not Eligible

You will not qualify if you...

  • Patients with severe pulmonary infections.
  • Patients with mental illness.
  • Patients with depression.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 28 days

Participants take oral medication—either Jiawei Bufei Tang granules or placebo—twice daily for 28 days, starting on the 7th day after surgery.

Daily oral medication for 28 days starting 7 days after surgery

Trial Site Locations

Total: 2 locations

1

Beijing cancer hospital

Beijing, Beijing Municipality, China, 100142

Actively Recruiting

2

Beijing cancer hospital

Beijing, Beijing Municipality, China, 100142

Actively Recruiting

Loading map...

Research Team

X

Xu yi chen, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Effectiveness of Acupuncture Combined With PD-1/PD-L1 Inhibi...

Lung Cancers

Actively Recruiting

3 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here